Results 211 to 220 of about 36,503 (286)

Exploring the Pharmacogenetic Landscape: Identification of Clinically Relevant Genotypes by a Nation-Wide Medical Testing Laboratory in Romania. [PDF]

Pharmaceuticals (Basel)
Pop C, Curici A, Voștinaru O, Apan A, Piciu A, Silaghi CA, Silaghi H, Popa SL, Dorobanțu FR, Mogoșan C.   +9 more
europepmc   +1 more source

CYP2C19 Loss-of-Function is an Associated Risk Factor for Premature Coronary Artery Disease: A Case–Control Study

International Journal of General Medicine
Wenhao Chen,1 Yuanliang Liu,2 Xunwei Deng,3 Bin Li,1 Hao Wang,1 Guoliang Wei,1 Kehui Chen,1 Shen Wang1 1Center for Cardiovascular Diseases, Meizhou People’s Hospital, Meizhou, People’s Republic of China; 2Department of Computer Tomography, Meizhou People’
Chen W, Liu Y, Deng X, Li B, Wang H, Wei G, Chen K, Wang S   +7 more
doaj  

Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors. [PDF]

Front Pharmacol
Wołowiec Ł, Osiak-Gwiazdowska J, Jaśniak A, Janiak M, Wydeheft L, Łukasiak M, Pellowska M, Grześk G.   +7 more
europepmc   +1 more source

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype [PDF]

, 2009
Ina M. Scholz, Heike Oberwittler, Klaus‐Dieter Riedel, Jürgen Burhenne, Johanna Weiß, Walter E. Haefeli, Gerd Mikus   +6 more
openalex   +1 more source

Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine. [PDF]

J Pers Med
Díaz-Villamarín X, Martínez-Pérez M, Nieto-Sánchez MT, Fernández-Varón E, Torres-García A, Blancas I, Cabeza-Barrera J, Morón R.   +7 more
europepmc   +1 more source

Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone [PDF]

, 2009
Susanne Löfgren, R. Michael Baldwin, Margareta Carlerös, Ylva Terelius, Ronny Fransson-Steen, Jessica Mwinyi, David J. Waxman, Magnus Ingelman‐Sundberg   +7 more
openalex   +1 more source

Ticagrelor versus clopidogrel in <i>CYP2C19</i> loss-of-function carriers with stroke or TIA stratified by age and renal function: CHANCE-2 trial substudy. [PDF]

Ren Fail
Wu Y, Zhou Y, Pan Y, Jin A, Meng X, Li H, Wang Y, Jiang Y, Wang Y.   +8 more
europepmc   +1 more source

Relation between CYP2C19 phenotype and genotype in a group of Brazilian volunteers [PDF]

, 2009
Rafael Linden, Ana Luíza Ziulkoski, Paula Tonello, Maína Wingert, André Arigony Souto   +4 more
openalex   +1 more source

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen [PDF]

, 2009
Matthew P. Goetz, Vera J. Suman
openalex   +1 more source

Genetic and clinical determinants of MACE and haemorrhage in antiplatelet therapy: insights from pharmacogenomic analysis. [PDF]

Front Cardiovasc Med
Wang Y, Yuan S, Li M, Feng W, Li J, Chen W, Berdi A, Kou Y, Yuan Y, Zhao J.   +9 more
europepmc   +1 more source